Literature DB >> 21647151

Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.

M G Loudin1, J Wang, H-C Eastwood Leung, S Gurusiddappa, J Meyer, G Condos, D Morrison, A Tsimelzon, M Devidas, N A Heerema, A J Carroll, S E Plon, S P Hunger, G Basso, A Pession, D Bhojwani, W L Carroll, K R Rabin.   

Abstract

Patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) have distinct clinical and biological features. Whereas most DS-ALL cases lack the sentinel cytogenetic lesions that guide risk assignment in childhood ALL, JAK2 mutations and CRLF2 overexpression are highly enriched. To further characterize the unique biology of DS-ALL, we performed genome-wide profiling of 58 DS-ALL and 68 non-DS (NDS) ALL cases by DNA copy number, loss of heterozygosity, gene expression and methylation analyses. We report a novel deletion within the 6p22 histone gene cluster as significantly more frequent in DS-ALL, occurring in 11 DS (22%) and only 2 NDS cases (3.1%) (Fisher's exact P=0.002). Homozygous deletions yielded significantly lower histone expression levels, and were associated with higher methylation levels, distinct spatial localization of methylated promoters and enrichment of highly methylated genes for specific pathways and transcription factor-binding motifs. Gene expression profiling demonstrated heterogeneity of DS-ALL cases overall, with supervised analysis defining a 45-transcript signature associated with CRLF2 overexpression. Further characterization of pathways associated with histone deletions may identify opportunities for novel targeted interventions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647151      PMCID: PMC4107887          DOI: 10.1038/leu.2011.128

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

Review 2.  Leukaemogenesis: more than mutant genes.

Authors:  Jianjun Chen; Olatoyosi Odenike; Janet D Rowley
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

3.  Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.

Authors:  Kelly W Maloney; William L Carroll; Andrew J Carroll; Meenakshi Devidas; Michael J Borowitz; Paul L Martin; Jeanette Pullen; James A Whitlock; Cheryl L Willman; Naomi J Winick; Bruce M Camitta; Stephen P Hunger
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

4.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.

Authors:  Gunnar Cario; Martin Zimmermann; Renja Romey; Stefan Gesk; Inga Vater; Jochen Harbott; André Schrauder; Anja Moericke; Shai Izraeli; Takashi Akasaka; Martin J S Dyer; Reiner Siebert; Martin Schrappe; Martin Stanulla
Journal:  Blood       Date:  2010-04-08       Impact factor: 22.113

5.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.

Authors:  Richard C Harvey; Charles G Mullighan; I-Ming Chen; Walker Wharton; Fady M Mikhail; Andrew J Carroll; Huining Kang; Wei Liu; Kevin K Dobbin; Malcolm A Smith; William L Carroll; Meenakshi Devidas; W Paul Bowman; Bruce M Camitta; Gregory H Reaman; Stephen P Hunger; James R Downing; Cheryl L Willman
Journal:  Blood       Date:  2010-02-04       Impact factor: 22.113

6.  Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

Authors:  Akinori Yoda; Yuka Yoda; Sabina Chiaretti; Michal Bar-Natan; Kartik Mani; Scott J Rodig; Nathan West; Yun Xiao; Jennifer R Brown; Constantine Mitsiades; Martin Sattler; Jeffrey L Kutok; Daniel J DeAngelo; Martha Wadleigh; Alfonso Piciocchi; Paola Dal Cin; James E Bradner; James D Griffin; Kenneth C Anderson; Richard M Stone; Jerome Ritz; Robin Foà; Jon C Aster; David A Frank; David M Weinstock
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-15       Impact factor: 11.205

7.  Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.

Authors:  Libi Hertzberg; Elena Vendramini; Ithamar Ganmore; Gianni Cazzaniga; Maike Schmitz; Jane Chalker; Ruth Shiloh; Ilaria Iacobucci; Chen Shochat; Sharon Zeligson; Gunnar Cario; Martin Stanulla; Sabine Strehl; Lisa J Russell; Christine J Harrison; Beat Bornhauser; Akinori Yoda; Gideon Rechavi; Dani Bercovich; Arndt Borkhardt; Helena Kempski; Geertruy te Kronnie; Jean-Pierre Bourquin; Eytan Domany; Shai Izraeli
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

8.  Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; J Racquel Collins-Underwood; Letha A A Phillips; Michael G Loudin; Wei Liu; Jinghui Zhang; Jing Ma; Elaine Coustan-Smith; Richard C Harvey; Cheryl L Willman; Fady M Mikhail; Julia Meyer; Andrew J Carroll; Richard T Williams; Jinjun Cheng; Nyla A Heerema; Giuseppe Basso; Andrea Pession; Ching-Hon Pui; Susana C Raimondi; Stephen P Hunger; James R Downing; William L Carroll; Karen R Rabin
Journal:  Nat Genet       Date:  2009-10-18       Impact factor: 38.330

9.  Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.

Authors:  Lisa J Russell; Melania Capasso; Inga Vater; Takashi Akasaka; Olivier A Bernard; Maria Jose Calasanz; Thiruppavaii Chandrasekaran; Elise Chapiro; Stephan Gesk; Mike Griffiths; David S Guttery; Claudia Haferlach; Lana Harder; Olaf Heidenreich; Julie Irving; Lyndal Kearney; Florence Nguyen-Khac; Lee Machado; Lynne Minto; Aneela Majid; Anthony V Moorman; Heather Morrison; Vikki Rand; Jonathan C Strefford; Claire Schwab; Holger Tönnies; Martin J S Dyer; Reiner Siebert; Christine J Harrison
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

10.  Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.

Authors:  Hannah M Ensor; Claire Schwab; Lisa J Russell; Sue M Richards; Heather Morrison; Dino Masic; Lisa Jones; Sally E Kinsey; Ajay J Vora; Christopher D Mitchell; Christine J Harrison; Anthony V Moorman
Journal:  Blood       Date:  2010-11-24       Impact factor: 22.113

View more
  22 in total

1.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  I-Ming Chen; Richard C Harvey; Charles G Mullighan; Julie Gastier-Foster; Walker Wharton; Huining Kang; Michael J Borowitz; Bruce M Camitta; Andrew J Carroll; Meenakshi Devidas; D Jeanette Pullen; Debbie Payne-Turner; Sarah K Tasian; Shalini Reshmi; Catherine E Cottrell; Gregory H Reaman; W Paul Bowman; William L Carroll; Mignon L Loh; Naomi J Winick; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2012-02-24       Impact factor: 22.113

Review 2.  Down syndrome: the brain in trisomic mode.

Authors:  Mara Dierssen
Journal:  Nat Rev Neurosci       Date:  2012-12       Impact factor: 34.870

3.  LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19.

Authors:  Hetty H Helsmoortel; Barbara De Moerloose; Tim Pieters; Farzaneh Ghazavi; Silvia Bresolin; Hélène Cavé; Andrica de Vries; Valerie de Haas; Christian Flotho; Veerle Labarque; Charlotte Niemeyer; Pascale De Paepe; Nadine Van Roy; Jan Stary; Marry M van den Heuvel-Eibrink; Yves Benoit; Johannes Schulte; Steven Goossens; Geert Berx; Jody J Haigh; Frank Speleman; Pieter Van Vlierberghe; Tim Lammens
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

4.  Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.

Authors:  Sarah K Tasian; Michelle Y Doral; Michael J Borowitz; Brent L Wood; I-Ming Chen; Richard C Harvey; Julie M Gastier-Foster; Cheryl L Willman; Stephen P Hunger; Charles G Mullighan; Mignon L Loh
Journal:  Blood       Date:  2012-06-08       Impact factor: 22.113

Review 5.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

6.  Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.

Authors:  L Olsson; A Castor; M Behrendtz; A Biloglav; E Forestier; K Paulsson; B Johansson
Journal:  Leukemia       Date:  2013-07-04       Impact factor: 11.528

7.  Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

Authors:  Omer Schwartzman; Angela Maria Savino; Michael Gombert; Chiara Palmi; Gunnar Cario; Martin Schrappe; Cornelia Eckert; Arend von Stackelberg; Jin-Yan Huang; Michal Hameiri-Grossman; Smadar Avigad; Geertruy Te Kronnie; Ifat Geron; Yehudit Birger; Avigail Rein; Giulia Zarfati; Ute Fischer; Zohar Mukamel; Martin Stanulla; Andrea Biondi; Giovanni Cazzaniga; Amedeo Vetere; Bridget K Wagner; Zhu Chen; Sai-Juan Chen; Amos Tanay; Arndt Borkhardt; Shai Izraeli
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 8.  Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.

Authors:  Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

9.  The intellectual disability of trisomy 21: differences in gene expression in a case series of patients with lower and higher IQ.

Authors:  André Mégarbané; Florian Noguier; Samantha Stora; Laurent Manchon; Clotilde Mircher; Roman Bruno; Nathalie Dorison; Fabien Pierrat; Marie-Odile Rethoré; Bernadette Trentin; Aimé Ravel; Marine Morent; Gerard Lefranc; David Piquemal
Journal:  Eur J Hum Genet       Date:  2013-02-20       Impact factor: 4.246

10.  Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic.

Authors:  Charles G Mullighan; Cheryl L Willman
Journal:  J Adolesc Young Adult Oncol       Date:  2011-06       Impact factor: 2.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.